非奈利酮联合恩格列净治疗慢性肾脏病与2型糖尿病
该研究为随机对照试验,纳入已使用肾素-血管紧张素系统抑制剂的慢性肾脏病合并2型糖尿病患者,随机分为非奈利酮组、恩格列净组及联合治疗组。主要终点为180天时尿白蛋白/肌酐比值较基线的相对变化。结果显示,联合治疗组尿白蛋白/肌酐比值降幅较非奈利酮单药组大29%,较恩格列净单药组大32%。两组单药及联合治疗均未出现预期外不良事件,症状性低血压、急性肾损伤及导致停药的高钾血症不常见。
要点
- 联合治疗组180天尿白蛋白/肌酐比值降幅较非奈利酮单药组大29%(最小二乘均值比值0.71,95%CI 0.61-0.82,P<0.001)。
- 联合治疗组180天尿白蛋白/肌酐比值降幅较恩格列净单药组大32%(最小二乘均值比值0.68,95%CI 0.59-0.79,P<0.001)。
- 症状性低血压、急性肾损伤及导致停药的高钾血症在单药及联合治疗中均不常见。
- 联合治疗未出现预期外不良事件。
适用人群与场景
- 慢性肾脏病(估算肾小球滤过率30至90 ml/min/1.73 m²)合并2型糖尿病、尿白蛋白/肌酐比值100至≤5000(白蛋白以毫克计、肌酐以克计)、且已使用肾素-血管紧张素系统抑制剂的患者。
处置流程与药物剂量
- 非奈利酮10或20 mg每日一次(联合恩格列净匹配安慰剂)。
- 恩格列净10 mg每日一次(联合非奈利酮匹配安慰剂)。
- 非奈利酮联合恩格列净(剂量同单药组)。
研究设计与关键结果
- 研究为随机对照试验,参与者按1:1:1随机分配至非奈利酮组、恩格列净组或联合治疗组;基线尿白蛋白/肌酐比值中位数579(四分位距292至1092),有可用数据者联合治疗组265例、非奈利酮组258例、恩格列净组261例。
- 主要终点为基线至180天对数转换平均尿白蛋白/肌酐比值的相对变化;联合治疗组降幅较非奈利酮单药组大29%(最小二乘均值比值0.71,95%CI 0.61-0.82,P<0.001)。
- 联合治疗组降幅较恩格列净单药组大32%(最小二乘均值比值0.68,95%CI 0.59-0.79,P<0.001)。
- 单药或联合治疗均未导致预期外不良事件;症状性低血压、急性肾损伤及导致停药的高钾血症不常见。
证据类型、等级与局限
- 研究类型:随机对照试验(CONFIDENCE,ClinicalTrials.gov NCT05254002)。
- 资助:Bayer。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在慢性肾脏病合并2型糖尿病患者中,初始联合非奈利酮与恩格列净较任一单药治疗可更大幅度降低尿白蛋白/肌酐比值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Limited evidence exists to support the simultaneous initiation of sodium-glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chronic kidney disease and type 2 diabetes.
METHODS: We randomly assigned participants with chronic kidney disease (estimated glomerular filtration rate [eGFR], 30 to 90 ml per minute per 1.73 m2 of body-surface area), albuminuria (a urinary albumin-to-creatinine ratio of 100 to ≤5000 [with albumin measured in milligrams and creatinine measured in grams]), and type 2 diabetes, who were already taking a renin-angiotensin system inhibitor, in a 1:1:1 ratio to receive finerenone (with empagliflozin-matching placebo) at a dose of 10 or 20 mg per day, empagliflozin at a dose of 10 mg per day (with finerenone-matching placebo), or a combination of finerenone and empagliflozin. The primary outcome was the relative change in the log-transformed mean urinary albumin-to-creatinine ratio from baseline to 180 days. Safety was assessed.
RESULTS: At baseline, the urinary albumin-to-creatinine ratio was similar among the participants in the three groups; the median value was 579 (interquartile range, 292 to 1092) among those with available data (265 in the combination-therapy group, 258 in the finerenone group, and 261 participants in the empagliflozin group). At day 180, the reduction in the urinary albumin-to-creatinine ratio with combination therapy was 29% greater than that with finerenone alone (least-squares mean ratio of the difference in the change from baseline, 0.71; 95% confidence interval [CI], 0.61 to 0.82; P<0.001) and 32% greater than that with empagliflozin alone (least-squares mean ratio of the difference in the change from baseline, 0.68; 95% CI, 0.59 to 0.79; P<0.001). Neither agent, alone or in combination, led to unexpected adverse events. Symptomatic hypotension, acute kidney injury, and hyperkalemia leading to drug discontinuation were uncommon.
CONCLUSIONS: Among persons with both chronic kidney disease and type 2 diabetes, initial therapy with finerenone plus empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either treatment alone. (Funded by Bayer; CONFIDENCE ClinicalTrials.gov number, NCT05254002.).
参考来源
- Agarwal R, Green JB, Heerspink HJL, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025. PMID: 40470996. doi:10.1056/NEJMoa2410659
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。